CASP10 (Caspase 10)

Notably, recombinant TRAIL protein synergizes with SGI1027 or MS1129 to kill VHL-deficient ccRCC in mice. Collectively, our study unveils an apoptosis induction strategy that involves hijacking HIFs for ccRCC treatment.

This study is the first to demonstrate the potent anti-melanoma effect of atranorin. This demonstrates the natural compounds' effects on cell proliferation, cell cycle progression, and the suppression of metastasis. These findings emphasize the potential of atranorin as a novel natural compound for use in adjunctive or targeted melanoma therapy, and highlight the need for further preclinical and clinical evaluation.

The cytotoxic activity of the synthesized compounds was evaluated against MCF-7 breast cancer cells, revealing IC50 values of 29.44 μM for PZ-9 and 17.35 μM for PZ-11, compared to 6.45 μM for the reference drug vincristine...PZ-11 is a promising TZD-based anticancer drug candidate against breast cancer cells, as determined by computational and experimental analysis. However, further validation is required through in vivo analysis to support these findings.

This study identified 13 new susceptibility genes significantly associated with PCa risk and provided new insights into the genetic basis of PCa, contributing to a more comprehensive understanding of its complex genetic structure.

The TME-specific gene-based prognostic model effectively predicts survival outcomes in pediatric brain tumors, offering promising biomarkers for personalized medicine and potential therapeutic targets. However, further research is required to validate these findings across different tumor subtypes and to explore their clinical applications.

Additionally, suppression of IL-6, TNF-α, and ECM remodeling factors indicated reduced metastatic potential. This strategy highlights NO-mediated synergy as a promising approach to overcome chemoresistance in TNBC.

We describe a differential expression of BCL2, BOK, BAD, and MCL1 and methylation of BOK and ESR1 genes in PCa in this study population for the first time. These differentially expressed and methylated genes can be explored for differential diagnosis, monitoring of treatment and new therapeutic targets.

In vivo, on day 25 of administration, tumor inhibition rates in T24 and EJ-1 tumor-bearing mice were up to 75.24% and 47.43%, respectively, in the ILL high-dose-treated and 71.58% and 43.89%, respectively, in the ILL low-dose-treated groups. Isolinderalactone controls BC progression by inducing apoptosis, suggesting that ILL may be an effective drug for the treatment of BC.

Finally, WB analysis validated the overexpression of CASP10 in LIHC and STAD tissues. Our comprehensive bioinformatic analysis reveal the function of CASP10 on the diagnosis, prognosis, and progression of diverse cancer types.

Subsequently, we conducted drug sensitivity analysis and immune checkpoint analysis, revealing that the majority of drugs are more sensitive to low-risk patients, while ABT-888, AS601245, and CCT007093 may have greater potential clinical benefits for high-risk patients. Immune checkpoint analysis showed significant differences in the expression of ADORA2A, BTLA, CD276, CD27, CD28, CD40LG, CD48, and TNFRSF14 between high-risk and low-risk patient groups, suggesting their potential as therapeutic targets for LUAD..

Importantly, CARP2 targets Golgin45 for ubiquitination and degradation in EGF-stimulated cells. Collectively, our findings unravel the existence of crosstalk between endosomal ubiquitin signaling and Golgi dynamics.

We compare activation of p53 target genes by novel compounds PG3 and PG3-Oc, that activate p53-target genes in a p53-independent manner, and four mutant p53-activating compounds while Nutlin-3a is used as negative control...We provide a novel mechanism engaged by PG3 to induce cell death via the HRI/ATF4/PUMA axis. Our results provide unique insights into the mechanism of action of PG3 as a novel cancer therapeutic targeting p53 pathway-like tumor suppression.